The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.

Rationale The response characteristics of the 6 minute walk test (6MWT) in studies of idiopathic pulmonary fibrosis (IPF) are only poorly understood, and the change in walk distance that constitutes the minimum important difference (MID) over time is unknown. Objectives To examine changes over time in distance walked (ie, 6MWD) during the 6MWT and to estimate the change in distance that constitutes the MID in patients with IPF. Methods Data from a recently completed trial that included subjects with IPF who completed the 6MWT, Saint George's Respiratory Questionnaire (SGRQ) and forced vital capacity (FVC) at 6 and 12  months were used to examine longitudinal changes in 6MWD. Both anchor- and distribution-based approaches as well as linear regression analyses were used to determine the MID for 6MWD. The SGRQ Total score and FVC were used as clinical anchors. Main results Among 123 subjects alive and able to complete the 6MWT at both follow-up time points, 6MWD did not change significantly over time (378.1 m at baseline vs 376.8 m at 6 months vs 361.3 m at 12 months, p=0.5). The point estimate for the 6MWD MID was 28 m with a range of 10.8–58.5 m. Conclusion In a group of patients with IPF with moderate physiological impairment, for those alive and able to complete a 6MWT, 6MWD does not change over 12 months. At the population level, the MID for 6MWD appears to be ∼28 m. Further investigation using other anchors and derivation methods is required to refine estimates of the MID for 6MWD in this patient population.

[1]  D. Lynch,et al.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[2]  G. Raghu,et al.  The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. , 2010, Respiratory medicine.

[3]  A. Holland,et al.  Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. , 2009, Respiratory medicine.

[4]  G. Raghu,et al.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. , 2008, American journal of respiratory and critical care medicine.

[5]  R. D. Bois,et al.  CATEGORICAL DECLINES IN PERCENT PREDICTED FORCED VITAL CAPACITY (PP-FVC) ARE ASSOCIATED WITH A GRADED RISK OF DEATH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) , 2008 .

[6]  H. Schünemann,et al.  The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease , 2008, Health and quality of life outcomes.

[7]  Y. Kondoh,et al.  Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis , 2008, Respirology.

[8]  Sally J. Singh,et al.  Minimum clinically important improvement for the incremental shuttle walking test , 2008, Thorax.

[9]  G. Raghu,et al.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.

[10]  Y. Kondoh,et al.  Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD. , 2007, Respiratory medicine.

[11]  K. Imanaka,et al.  Health-related quality of life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal study. , 2007, Internal medicine.

[12]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. , 2006, American journal of respiratory and critical care medicine.

[13]  A. Stewart,et al.  Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives , 2005, Health and quality of life outcomes.

[14]  M. Gould,et al.  Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review , 2005, Thorax.

[15]  A. Wells,et al.  Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. , 2005, American journal of respiratory and critical care medicine.

[16]  S. Kudoh,et al.  Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.

[17]  Y. Kondoh,et al.  Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? , 2005, Respiratory medicine.

[18]  D. Mahler,et al.  The MCID of the Transition Dyspnea Index is a Total Score of One Unit , 2005, COPD.

[19]  R. Hays,et al.  Approaches and Recommendations for Estimating Minimally Important Differences for Health-Related Quality of Life Measures , 2005, COPD.

[20]  Cynthia D. Brown,et al.  Minimal Clinically Important Differences in the Six-Minute Walk Test and the Incremental Shuttle Walking Test , 2005, COPD.

[21]  L. Léger,et al.  A maximal multistage 20-m shuttle run test to predict $$\dot V$$ O2 max , 2004, European Journal of Applied Physiology and Occupational Physiology.

[22]  G. Guyatt,et al.  Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. , 2003, Journal of clinical epidemiology.

[23]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[24]  H. Collard,et al.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[25]  F. Martinez,et al.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[26]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[27]  J. Brazier,et al.  What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D , 2003, Health and quality of life outcomes.

[28]  U. Costabel,et al.  ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias , 2002, European Respiratory Journal.

[29]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[30]  J. Tooze,et al.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. , 2001, American journal of respiratory and critical care medicine.

[31]  R. Hubbard,et al.  A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis , 2001, Thorax.

[32]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[33]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[34]  James C. Raymondo,et al.  Statistical Analysis in the Behavioral Sciences , 1998 .

[35]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.

[36]  M. Muers,et al.  Reproducibility of walking test results in chronic obstructive airways disease. , 1988, Thorax.

[37]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.

[38]  G H Guyatt,et al.  How should we measure function in patients with chronic heart and lung disease? , 1985, Journal of chronic diseases.

[39]  G H Guyatt,et al.  Effect of encouragement on walking test performance. , 1984, Thorax.

[40]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.

[41]  A. Woodcock,et al.  Two-, six-, and 12-minute walking tests in respiratory disease. , 1982, British medical journal.

[42]  A H Morris,et al.  Standardized single breath normal values for carbon monoxide diffusing capacity. , 2015, The American review of respiratory disease.

[43]  J. Morris,et al.  Spirometric standards for healthy nonsmoking adults. , 2015, The American review of respiratory disease.

[44]  D L Adams,et al.  Analysis of a life satisfaction index. , 1969, Journal of gerontology.